Quantcast
Home > Quotes > CRIS
x
CRIS

Curis, Inc. Common Stock (CRIS) Quote & Summary Data

$2.06
*  
0.03
1.44%
Get CRIS Alerts
*Delayed - data as of Oct. 19, 2018  -  Find a broker to begin trading CRIS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 2.14 / $ 2.0465
Share Volume
178,962
50 Day Avg. Daily Volume
242,420
Previous Close
$ 2.09
52 Week High / Low
$ 8.70 / $ 1.36
Market Cap
68,353,161
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
178,962
50 Day Avg. Daily Volume:
242,420

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.41

Trading Range

The current last sale of $2.06 is 51.47% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.14 $ 8.70
 Low: $ 2.0465 $ 1.36

Company Description (as filed with the SEC)

We are a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers. Our clinical stage drug candidates are CUDC-907, which we are investigating in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and solid tumors, CA-170, for which we are currently conducting a Phase 1 study in patients with advanced solid tumors and lymphomas, and CA-4948, for which, in January 2018 we initiated a Phase 1 trial in patients with advanced non-Hodgkin lymphomas, including those with the myeloid differentiation primary response 88, or MYD88 alterations. Our pipeline also includes CA-327, which is a pre-IND stage oncology drug candidate. We expect to file an IND application with the United States Food and Drug Administration, or FDA, for clinical testing of CA-327 in 2018.  ... More ...  


Risk Grade

Where does CRIS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.09
Open Date:
Oct. 19, 2018
Close Price:
$ 2.06
Close Date:
Oct. 19, 2018

Consensus Recommendation

Analyst Info